XTX Topco Ltd Buys Shares of 22,972 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

XTX Topco Ltd bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,972 shares of the company's stock, valued at approximately $440,000.

Several other large investors also recently made changes to their positions in VRDN. R Squared Ltd bought a new position in Viridian Therapeutics in the 4th quarter worth approximately $26,000. AlphaQuest LLC grew its stake in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after purchasing an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after purchasing an additional 1,516 shares during the period. Quantbot Technologies LP bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at about $164,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Viridian Therapeutics in the fourth quarter worth about $219,000.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN traded down $0.06 on Friday, reaching $13.50. 524,676 shares of the company traded hands, compared to its average volume of 1,199,501. The stock has a market capitalization of $1.10 billion, a PE ratio of -3.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The company's 50 day moving average is $14.28 and its 200-day moving average is $18.34. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. As a group, analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.